Two strategies dominate the longevity field
How do you treat ageing? A new review in Signal Transduction and Targeted Therapy maps the landscape into two broad camps: clearing out exhausted cells, and adjusting how the body manages energy…
Ageing is not a single process. Cells become damaged, metabolism shifts, and patterns of gene activity change. But when you line up current research directions, two dominant strategies emerge. The authors lay out this framework in detail in their review article.
Clearing, suppressing, and reversing senescence
The first strategy targets senescent cells: cells that have stopped dividing but refuse to die. They secrete a cocktail of inflammatory signals that damage surrounding tissue. Three approaches are described. Senolytics are compounds that selectively kill senescent cells, the combination of dasatinib and quercetin is one example. Senomorphics suppress the harmful secretions of those cells without killing them; rapamycin is cited as an example. A third approach, senoreversion (reprogramming senescent cells through epigenetic modifications), remains largely in early stages.
Metabolism as the second track
The second category covers interventions that influence the body’s energy balance and cellular maintenance. Caloric restriction mimetics, compounds that replicate the effects of eating less without actual calorie reduction, are central here. Examples include spermidine, alpha-ketoglutarate, and ergothioneine. They activate autophagy, the process by which cells break down and recycle damaged components. In animal models, these compounds extended lifespan and improved health at older ages.
The authors acknowledge this is a simplification. Many interventions touch both categories simultaneously, and several important ageing mechanisms fall outside this framework entirely. Most results also come from animal studies. Whether and how these translate to humans remains an open question. As an orientation to the field, however, the review offers a useful map.